Repligen Corporation (NASDAQ:RGEN) today announced the launch of its new larger-scale OPUS™ brand chromatography columns used in the manufacture of biopharmaceuticals. The OPUS™ (Open Platform User Specified) line extension is being introduced in response to rising market demand for disposable technologies in biopharmaceutical manufacturing. Such technologies are revolutionizing biomanufacturing by enabling increased facility flexibility and operating efficiencies. The new OPUS™ chromatography columns are now commercially available to biopharmaceutical manufacturers and developers worldwide.
OPUS™ pre-packed, single-use plastic chromatography columns are suitable for multi-cycle purification of biologics such as monoclonal antibodies, proteins and vaccines. The OPUS™ product line is unique in providing customers with an open platform to accommodate an unprecedented range of options in chromatography media, column sizes and bed heights. The scalability and immediate “plug-and-play” usability of OPUS™ columns increases facility flexibility and can improve the speed of process development and reduce the cost of biopharmaceutical manufacturing by decreasing the set-up, cleaning and validation times associated with traditional purification technologies.
The OPUS™ line extension broadens the utility of OPUS™ columns to the production of a wider range of clinical stage biologics and niche commercial products such as orphan biologics. The Company estimates the total chromatography market for clinical stage biologics to be approximately $100 million.
“We are pleased to introduce our larger-scale OPUS™ columns to the biomanufacturing market. As with all of the chromatography products in the OPUS™ line, these new columns are uniquely customizable, being pre-packed with media of our customers’ choosing,” said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen Corporation. “We are encouraged by the early response to the new OPUS™ products from our current customers, as well as feedback from a number of potential new customers who have been seeking process scale single-use chromatography solutions.”
Repligen acquired the initial OPUS™ technology in March 2010 as part of the Company’s ongoing commitment to leverage its core competency in bioprocessing into a broader purification product offering to the pharmaceutical industry. The Company’s bioprocessing business now sells 16 products including: